One week after sharing plans for a widespread, nationwide market launch of VEVYE (cyclosporine ophthalmic solution) 0.1%, Harrow, Inc. announced that the newly FDA-approved product is now available in the United States for dry eye disease (DED) treatment.
Give me a rundown on the product, first.
The formulation was approved in May 2023 under its developer, Novaliq GmbH, before becoming acquired by Harrow in July 2023.
VEVYE (pronounced vee-vye) is a prescription-based, twice-daily (BID)-dosed formulation dispensed in a 10 microliter drop that contains proprietary, preservative- and water-free technology properties, as well as a low surface tension and viscosity.
See here for its prescribing info.
What’s so significant about it?
VEVYE’s approval marked it as the first and only cyclosporine solution indicated to treat the signs and symptoms of DED, with an efficacy demonstrated at 4 weeks in clinical trials.
And per Harrow, the solution is a, “unique combination of both a potent 0.1% cyclosporine solute and a pH- and osmolarity-free semifluorinated alkane.”
That’s pretty noteworthy …
Indeed it is. Learn more about the supporting clinical data from two phase 3 trials that led to its approval by clicking here.
Now, let’s talk about Harrow's plans for this product’s launch.
The company actually just announced last week that its partnering with three major healthcare technology platforms to support VEVYE’s launch, with an end-goal of ensuring patients in need of the product are able to access it, as CEO and Chairman Mark L. Baum previously said.
“VEVYE represents an important new prescription choice in the U.S. dry eye disease market, and we are excited to streamline the prior authorization process, guiding patients through their insurance coverage and ensuring competitive pricing – with minimum hassle,” he stated last week.
The partners include:
- PhilRx
- Apollo Care
- PARx Solutions
See here for our coverage on that, including details on each of the platforms.
How does ordering work, exactly?
According to Harrow, clinicians can use their respective electronic medical record (EMR) to send prescriptions directly to PhilRx, the company’s pharmacy partner, or to any retail pharmacy (which usually ships VEVYE within 24 hours of order placement).
See here for ordering details using PhilRx.
To note, VEVYE is also directly available via wholesale distributors such as McKeesson, Cardinal, and Cencora ( Amerisource Bergen).
What else is the company offering for patients?
In tandem with the product launch, Harrow also established the VEVYE Patient Access program and announced a 100% Money-Back Guarantee program (for one prescription fill of VEVYE).
The eligibility details on these two programs is key, though:
- VEVYE Patient Access program
- Only available for eligible commercially insured patients who are dispensed VEVYE by PhilRx or another participating pharmacy.
- Click here for details
- Click here for details
- Only available for eligible commercially insured patients who are dispensed VEVYE by PhilRx or another participating pharmacy.
- 100% Money-Back Guarantee program
- Available for patients who pay cash and who don’t have commercial or government insurance (like Medicare and Medicaid).
Click here for details